Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

774
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
774
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

663
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
663
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
Drug Therapy01:28

Drug Therapy

401
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
401
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.4K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.4K
Schizophrenia01:17

Schizophrenia

1.6K
Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neonatal vitamin D levels and autoimmune disorders: a Danish population-based cohort study.

European journal of epidemiology·2026
Same author

Cochrane Evaluation of (Semi-) Automated Review Methods (CESAR): Protocol for an adaptive platform study within reviews.

Journal of clinical epidemiology·2026
Same author

Operation Stork Speed represents an opportunity to reform infant formula clinical trials.

Nature food·2026
Same author

Neonatal vitamin D status and asthma risk after age 5 years: A Danish population-based cohort study.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

Sibling Comparison Designs to Assess Social Exposures and Empirical Tools to Guide Interpretation: An Illustrative Study of Childhood Income and Subsequent Mental Disorders.

Epidemiology (Cambridge, Mass.)·2025
Same author

Schizophrenia.

Nature reviews. Disease primers·2025

Related Experiment Video

Updated: Mar 31, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K

Lithium for schizophrenia.

Stefan Leucht1, Bartosz Helfer, Markus Dold

  • 1Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Ismaninger Straße 22, München, Germany, 81675.

The Cochrane Database of Systematic Reviews
|October 29, 2015
PubMed
Summary
This summary is machine-generated.

Lithium is not effective as a sole treatment for schizophrenia. While lithium augmentation shows some promise for antipsychotic treatment, the evidence is low quality and inconclusive for schizophrenia patients.

More Related Videos

The Tail Suspension Test
10:17

The Tail Suspension Test

Published on: January 28, 2012

84.1K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.9K

Related Experiment Videos

Last Updated: Mar 31, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K
The Tail Suspension Test
10:17

The Tail Suspension Test

Published on: January 28, 2012

84.1K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.9K

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Trials

Background:

  • Schizophrenia treatment often involves antipsychotic drugs, but many patients show inadequate response.
  • Lithium is sometimes used as an adjunctive therapy in such cases.

Purpose of the Study:

  • To evaluate lithium monotherapy for schizophrenia, schizophrenia-like psychoses, and schizoaffective disorders.
  • To assess the efficacy of lithium augmentation in conjunction with antipsychotic medications for these conditions.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs).
  • Searched major databases up to January 2015, including pharmaceutical company data.
  • Included 22 studies with 763 participants, assessing lithium versus placebo, antipsychotics, or as augmentation.

Main Results:

  • No evidence supports lithium as a sole treatment for schizophrenia.
  • Lithium augmentation showed a potential benefit in response rates, but this was not significant when excluding certain study types or participants.
  • Limited data on side effects, with no significant differences reported but insufficient information on known lithium risks.

Conclusions:

  • The evidence base for lithium in schizophrenia is limited by low methodological quality.
  • Further large, well-designed trials are needed, particularly for patients with core schizophrenia symptoms and those with schizoaffective disorders.